Dopamine agonist for the rapid improvement of visual field defects in giant and macro-prolactinomas.
Sign Up to like & getrecommendations! Published in 2022 at "Journal francais d'ophtalmologie"
DOI: 10.1016/j.jfo.2022.01.002
Abstract: PURPOSE To evaluate effect of first-line dopamine agonist (DA) therapy as an alternative to surgery for visual field defect (VFD) recovery in giant and macro-prolactinoma. METHODS In this retrospective study, 125 patients with giant and… read more here.
Keywords: dopamine agonist; giant macro; macro prolactinomas; visual field ... See more keywords